Samsara Vision Files SEC Paperwork for $25 Million IPO to Advance IMT

Samsara Vision, of Far Hills, New Jersey, plans to raise $25 million in an initial public offering to advance a next-generation version of its Implantable Miniature Telescope (by Dr. Isaac Lipshitz), according to paperwork filed with the US SEC on Jan. 7. The company, previously known as VisionCare, plans to offer 4,166,667 shares of common stock at $6 per share …

EyeD Pharma Raises $51 Million to Advance Intraocular Drug Implants

Belgium-based EyeD Pharma announced Dec. 22 that it had raised €45 million (US $51 million) in a funding round backed by a mix of private and public investors. The company said the funding would allow it to advance its lead candidate TimoD into human trials. TimoD is a non-biodegradable intraocular implant designed to deliver a controlled dose of the glaucoma drug …

Rayner Launches Blue Light-Filtering IOL in Europe, Gets FDA Green Light to Begin US Trial of Trifocal Lenses

UK-based ophthalmic company Rayner announced Jan. 5 that it had launched the RayOne Hydrophobic BLF, the company’s first blue light-filtering IOL, in Europe. The lens is available from 0.0 diopters to +32.0 diopters in countries accepting CE-marked products. It expands the RayOne portfolio to eight models. Rayner CEO Tim Clover said of the launch: “Over a third of all lenses …

Belkin Vision to Receive €17.5M Grant from European Innovation Council

Belkin Vision announced that it has received €17.5M of blended financing in grants and equity from the European Innovation Council Accelerator (EIC). Belkin Vision’s glaucoma laser is currently in the final stages of clinical trials across the UK and Europe, and if approved, would be the first and only contactless laser treatment for glaucoma, according to a company news release.

OKYO Says its Anti-inflammatory Dry Eye Candidate Also Reduces Ocular Pain

OKYO Pharma, of London, announced Dec. 13 that its first drug candidate, OK-101, developed to treat dry eye disease as an anti-inflammatory, also showed potent ocular pain reducing properties in a mouse model. OK-101 is a novel, long-acting G protein-coupled receptor-based lipidated chemerin peptide developed to bind to ChemR23 receptors in the eye and interrupt the inflammatory response.

Nicox Raises $16.9 Million in Private Placement

French company Nicox announced Dec. 9 that it had raised €15 million (US $16.9 million) through a private placement of 6 million new ordinary shares. Warrants issued in the private placement could provide an additional €16.4 million (US $18.5 million) in gross proceeds if they were to be fully exercised, Nicox said.

Kiora Reports KIO-101 is Safe and Tolerable for Dry Eye Disease

Kiora Pharmaceuticals announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a driver of dry eye disease. The results demonstrated favorable safety and tolerability of KIO-101 as well as statistically significant improvements in conjunctival hyperemia, a key inclusion criterion for the 21 patients …